Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554105 | 1.00 | AAK1 (0.51) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL21732913 | 0.88 | AAK1 (0.51) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL1818990 | 0.88 | ITGB3 (0.56) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL1818988 | 0.88 | ITGB3 (0.56) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL17459578 | 0.88 | AAK1 (0.51) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL5892821 | 0.88 | ITGB3 (0.56) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL17459580 | 0.88 | AAK1 (0.51) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL30400176 | 0.87 | AAK1 (0.50) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL539839 | 0.87 | AAK1 (0.50) | AAK1CTSSCTSKCTSBCTSL | |
| SCHEMBL539840 | 0.87 | AAK1 (0.50) | AAK1CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2024-12-19 | — | — | US | disclosed |
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC | 2020-11-03 | — | — | US | disclosed |
| US-20180237381-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-08-23 | — | — | US | disclosed |
| EP-3337497-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | Portola Pharmaceuticals, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034994-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOL1 | AAK1 2182/4885CTSS 1321/4885CTSK 1103/4885 |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOB | AAK1 2211/4885CTSS 1028/4885CTSK 936/4885 |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | AAK1 2211/4885CTSS 1028/4885CTSK 936/4885 |
| US-20180237381-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | AAK1 2211/4885CTSS 1028/4885CTSK 936/4885 |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | AAK1 2211/4885CTSS 1028/4885CTSK 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.